What Fosun Pharma does

Fosun Pharma (Shanghai Fosun Pharmaceutical Group Co., Ltd.) is an innovation-driven global pharmaceutical and healthcare group founded in 1994 and dual-listed on the Shanghai Stock Exchange (600196.SH) and Hong Kong Stock Exchange (02196.HK). The company directly operates four business segments — pharmaceutical manufacturing, medical devices and diagnostics, healthcare services through 30+ Fosun Health hospitals, and a ~25% stake in Sinopharm covering pharmaceutical distribution and retail — while serving patients and healthcare systems across more than 90 countries. Its pharmaceutical portfolio spans innovative drugs (serplulimab, the first anti-PD-1 mAb approved for first-line small cell lung cancer globally; luvometinib for LCH/NF1; CDK4/6 inhibitor FCN-437c), biosimilars (Hanlikang rituximab, Hanquyou/Zercepac trastuzumab, Handayuan adalimumab, Hanbeitai bevacizumab), cell therapies (Yikaida CAR-T, FKC-289 dual-target CAR-T), and global health products such as WHO-prequalified Artesun for severe malaria. Technology platforms include antibody and ADC capabilities (FS-1502 HER2 ADC, HLX43 PD-L1 ADC), the Astrolabe AI drug discovery system, and integrated R&D data infrastructure via AquaVista.

The company monetizes through a multi-channel model: direct hospital sales and tendering across China, licensing and royalty streams from international partners (Eisai for serplulimab in Japan, Pfizer for the YP05002 GLP-1 agonist, AriBio for AR1001 in Alzheimer's and ASEAN), subsidiary-led commercialization (Henlius in EU/China, Sisram Medical in aesthetics, Breas in respiratory, Fosun Diagnostics in IVD), and a 25% economic interest in Sinopharm's distribution network. R&D investment reached RMB 5.913 billion in 2025, supported by 3,145 R&D personnel operating across Shanghai, Taipei, California, New Jersey, Boston, Tokyo, and Mumbai, with 80+ active clinical projects and 16 marketed products as of early 2026. Revenue grew 1.45% YoY to RMB 41.662 billion in 2025 with net profit up 21.69% YoY to RMB 3.371 billion, while innovative drug revenue grew 18.09% YoY in the first three quarters, signaling a mix shift toward higher-margin proprietary products and licensing income.

Name

Fosun Pharma

Legal name

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海复星医药（集团）股份有限公司）

Website

https://fosunpharma.com

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fosun Pharma is a Shanghai-headquartered, dual-listed (A+H) global pharmaceutical and healthcare group developing innovative drugs, biosimilars, cell therapies, and diagnostics for oncology, infectious disease, and rare diseases across 90+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Services-Hospitals (8060), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Innovative pharmaceutical development
• Oncology biosimilar manufacturing
• Cell therapy development
• Medical diagnostic devices
• Healthcare services operations

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Core revenue stream from pharmaceutical manufacturing and sales including innovative drugs, generics, and biosimilars. Products span oncology, immunology, infectious diseases, and chronic conditions. Revenue reached RMB 41.662 billion in 2025.
2. Medical Devices and Diagnostics: Revenue from medical aesthetic devices (Sisram Medical), respiratory equipment (Breas), diagnostic reagents and equipment (Fosun Diagnostics), and surgical robots.
3. Healthcare Services: Revenue from healthcare services through Fosun Health hospitals and clinics, covering over 30 hospitals across major economic zones in China.
4. Pharmaceutical Distribution: Through 25% stake in Sinopharm (国药控股), covering pharmaceutical wholesale and retail distribution across China.
5. Licensing and Co-development: Revenue from out-licensing innovative drugs to global pharmaceutical companies. Notable deals include serplulimab licensed to Eisai for $4 billion-plus potential value, and GLP-1 agonist YP05002 licensed to Pfizer for up to $1.94 billion plus royalties.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Fosun Pharma is an innovation-driven global pharmaceutical and healthcare group that develops, manufactures, and commercializes innovative drugs, biosimilars, cell therapies, vaccines, medical devices, and diagnostics. Its directly operated businesses span pharmaceuticals, medical devices & diagnostics, and healthcare services, complemented by a ~25% stake in Sinopharm for pharmaceutical distribution. The company markets products including serplulimab (first-in-class anti-PD-1 for SCLC), trastuzumab biosimilar, China's first approved CAR-T therapy, and Artesun antimalarial across 90+ countries.

Product overview

Fosun Pharma is an innovation-driven global pharmaceutical and healthcare group operating pharmaceutical manufacturing, medical devices/diagnostics, and healthcare services businesses. Core pharmaceutical products include innovative drugs (汉斯状® serplulimab for oncology, 复迈宁® FCN-159 for rare diseases), biosimilars (汉利康® rituximab, 汉曲优® trastuzumab), and cell therapies (奕凯达® CAR-T). The company also operates medical aesthetic devices through Sisram Medical, respiratory devices through Breas, and IVD products through Fosun Diagnostics. Supportive care products include antiemetic 奥康泽® and G-CSF 珮金®, marketed under the 支点 platform. The AI-powered R&D platforms include PharmaAID for strategic intelligence, Astrolabe for drug discovery, MedAlkaid for clinical research, and AquaVista for clinical data integration.

Differentiator

Problem solved

Functional benefit

Brands

• 汉利康 (Hanlikang): Rituximab injection - China's first approved biosimilar drug
• 汉曲优 (Hanquyou / Zercepac)
• 汉斯状 (Hansizhuang / Serplulimab)
• 奕凯达 (Yikai Da)
• 苏可欣 (Sukexin)
• 复必泰
• Artesun (注射用青蒿琥酯)
• 汉达远 (Handayuan)
• 汉贝泰 (Hanbeitai)
• 奥康泽 (Aokangze)
• 珮金 (Peijin)
• 复迈宁 (Fumaining)
• 复宏汉霖 (Henlius)
• 复星诊断 (Fosun Diagnostics)
• 复锐医疗科技 (Sisram Medical, 1696.HK)
• 复星健康 (Fosun Health)
• 博毅雅 (Breas)
• 达芬奇手术机器人

Products and services

• Artesun (注射用青蒿琥酯) Self-developed antimalarial innovative drug, WHO-recommended first-line treatment for severe malaria, used in African and Asian healthcare systems through partnerships and donations.
• Hanlikang (汉利康, rituximab injection) China's first approved biosimilar (rituximab) for treating lymphoma, benefiting over 100,000 Chinese patients since 2019 approval.
• Hanquyou / Zercepac (汉曲优, trastuzumab injection) First China-EU dual-approved monoclonal antibody biosimilar (trastuzumab) for HER2-positive breast and gastric cancer, marketed as Zercepac in nearly 20 European countries.
• HANSIZHUANG / Hetronifly (汉斯状, serplulimab injection) Self-developed anti-PD-1 monoclonal antibody, world's first approved for first-line treatment of small cell lung cancer, approved in China, EU, and over 40 countries.
• Yikaida (奕凯达, axicabtagene ciloleucel injection) China's first approved CAR-T cell therapy for relapsed or refractory large B-cell lymphoma, covered by 60+ city惠民保 programs and commercial insurance plans.
• Sukexin (苏可欣, avatrombopag maleate tablets) First imported small molecule innovative drug by Fosun Pharma and China's first approved drug for chronic liver disease-related thrombocytopenia (CLDT), included in national medical insurance since 2020.
• BNT162b2 mRNA COVID-19 vaccine (复必泰) mRNA COVID-19 vaccine co-developed with BioNTech, registered in Hong Kong and Macau for both public and private market use.
• Luvometinib / Fumaining (复迈宁, FCN-159) MEK1/2 selective inhibitor approved in China for treatment of NF1-related plexiform neurofibromas in adults and Langerhans cell histiocytosis (LCH) in pediatric patients 2+ years.
• HLX43 (PD-L1 ADC) PD-L1 antibody-drug conjugate in pivotal clinical development globally for multiple oncology indications.
• AR1001 (Alzheimer's disease PDE5 inhibitor) Oral PDE5 inhibitor for Alzheimer's disease currently in global Phase 3 POLARIS-AD trial with over 1,500 patients enrolled, licensed globally by Fosun Pharma from AriBio.
• FCN-437c (复妥宁, CDK4/6 inhibitor) CDK4/6 inhibitor approved for 2 breast cancer indications in China, providing new treatment options for breast cancer patients.
• Breyanzi (布瑞基奥仑赛) Second CAR-T cell therapy product with NDA accepted for review by Chinese regulatory authorities.
• YP05002 (GLP-1 receptor agonist) Small molecule GLP-1 receptor agonist licensed globally to Pfizer for chronic weight management, in Phase 1 development.
• Nacubactam (OP0595) Novel β-lactamase inhibitor with dual mechanism (independent antibacterial activity via PBP2 binding plus β-lactam enhancement), Phase 3 results published in The Lancet for resistant bacterial infections.
• FKC-289 (autologous dual-target CAR-T) Autologous dual-target CAR-T product targeting BCMA and CD19, approved for clinical trials in China for relapsed/refractory membranous nephropathy and light-chain amyloidosis.
• Da Vinci Surgical System (达芬奇手术机器人) FDA-approved robotic-assisted laparoscopic surgery system, the most widely used minimally invasive surgery robot globally, distributed in China.
• Sisram Medical Aesthetic Devices Medical aesthetic equipment platform under Sisram Medical (1696.HK), covering energy-based devices, injectables, dental aesthetics, and personal care products.
• Breas Respiratory Products Professional mechanical ventilation products from Sweden-based Breas, serving patients in over 40 countries with Z1 Auto, iSleep, Vivo, and Clearway series.
• Fosun Diagnostics IVD Products In vitro diagnostics products covering clinical chemistry, immunoassay, molecular diagnostics, microbiology, and POCT across six disease areas including oncology, metabolic, cardiovascular, and infectious diseases.
• Aokangze (奥康泽, netupitant palonosetron capsule) Novel antiemetic combining NK1 receptor antagonist netupitant with 5-HT3 antagonist palonosetron for prevention of chemotherapy-induced nausea and vomiting (CINV). Only fixed-dose combination globally with synergistic effect.
• Peijin (珮金, laperfilgrastim injection) Long-acting G-CSF with proprietary 40kD Y-type PEG structure, approved June 2023 for preventing chemotherapy-induced febrile neutropenia. Only 2mg low-dose regimen among long-acting G-CSFs with lower bone pain incidence.
• Handayuan (汉达远, adalimumab biosimilar) Adalimumab biosimilar for autoimmune diseases, priced at RMB 899 per vial to bring adalimumab into the hundreds-of-yuan era in China for improved patient accessibility.
• Fosun Health Hospital Network Services Healthcare services through over 30 Fosun Health hospitals and clinics across major Chinese economic zones, with online-offline integrated healthcare platform via Fosun Health APP and WeChat Mini Program.
• PharmAID AI Pharmaceutical Intelligence Platform Enterprise AI-powered decision support platform combining LLMs, deep reasoning architecture, multi-source industry data, and AI Agent capabilities for pharmaceutical R&D intelligence, strategic analysis, and clinical workflow optimization.
• Astrolabe (星图计划) AI Drug Discovery Platform AI drug discovery model system for multi-modal drug development covering small molecules, oligonucleotides, and biologics, with node-level modeling and dry-wet closed-loop iteration.

Quantifiable outcome

• 88 million+ severe malaria patients treated globally with Artesun
• +4 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

• AriBiocoreStrategic or Co-development Partner · 14 May 2026Exclusive global option agreement for AR1001, an oral PDE5 inhibitor for Alzheimer's disease. Fosun paid $60 million upfront with potential additional payments of up to $180 million in milestone payments and further sales milestones tied to annual net sales of at least $2.5 billion. Phase 3 POLARIS-AD trial has enrolled over 1,500 patients with results expected in 2026.
• Arcera Life SciencesstrategicStrategic or Co-development Partner · 29 April 2026MoU for neuroscience innovation collaboration leveraging Fosun Pharma's research and manufacturing strengths with Arcera's access to international markets. Exploring radiopharmaceuticals, biologics, small molecules, siRNA therapies, and cell and gene therapies.
• Arcera Life SciencesstrategicStrategic or Co-development Partner · 28 April 2026MoU signed April 28, 2026 for long-term strategic collaboration focused on licensing, frontier technology incubation, and neuroscience innovation. Initial focus on oncology, neuroscience, rare diseases, and cardiometabolic disease. Aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030.
• Sisram Medical (复锐医疗科技)minorStrategic or Co-development Partner · 21 January 2026Sisram Medical partnered with Sinmait Medical Technology (Shanghai Fosun Pharmaceutical subsidiary) to establish manufacturing and innovation hub in China for Energy-Based Devices (EBD) localization and APAC market supply chain resilience.
• Aditum Bio (Clavis Bio)strategicStrategic or Co-development Partner · 19 December 2025Five-year collaboration through which Aditum launched Clavis Bio for novel therapy development. Fosun holds exclusive rights to develop, manufacture and commercialize partnered assets in China, Hong Kong and Macau, while Clavis can license programs elsewhere. Potential payments to Fosun of up to $362.50 million plus milestones and royalties.
• Green Valley PharmaceuticalsstrategicStrategic or Co-development Partner · 16 December 2025Fosun Pharma spending 1.4 billion yuan ($200 million) to acquire 53% stake in Green Valley to revive sodium oligomannate (GV-971), a controversial Alzheimer's drug. Deal aims to expand CNS product pipeline and address unmet treatment needs.
• Sinopharm (国药控股)coreChannel Partner/ Reseller/ DistributorFosun Pharma holds approximately 25% stake in Sinopharm, China's largest pharmaceutical distributor. Partnership covers pharmaceutical wholesale and retail distribution across China through Sinopharm's extensive network.
• Insilico MedicinestrategicTechnology or IntegrationAI-driven drug discovery collaboration where Fosun Pharma has an out-licensed program with Insilico Medicine. Insilico has three out-licensed programs including one with Fosun Pharma, contributing to AI drug discovery ecosystem.

Scale indicators20 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• Hengrui Medicine: China's largest innovative pharmaceutical company with comparable oncology and innovative drug pipeline. Both are major Chinese pharma players pivoting from generics to innovation with global ambitions and similar therapeutic area focus including oncology and autoimmune diseases.
• BeiGene: Global oncology-focused Chinese biotech with approved PD-1 (Tislelizumab) and BTK inhibitor (Zanubrutinib). Direct comparable to Fosun's innovative oncology franchise, both companies pursue global development with multi-region clinical trials and have achieved multiple first-in-class/best-in-class positions in oncology.
• Innovent Biologics: Chinese biotech with PD-1 (sintilimab) and expanding innovative oncology/immunology pipeline. Competes with Fosun's serplulimab in Chinese PD-1 market and shares similar biosimilar/innovative drug dual-track strategy with major pharma licensing partnerships.
• Junshi Biosciences: Chinese PD-1 pioneer (toripalimab) with global expansion strategy. Direct head-to-head competitor to Fosun's serplulimab in the anti-PD-1 mAb space, both pursuing first-in-class/best-in-class positioning across oncology indications including rare cancers.
• Akeso, Inc. Chinese biotech with strong oncology pipeline including bispecific antibodies (PD-1/VEGF cadonilimab). Comparable innovation-focused strategy with Fosun, both pursuing FIC/BIC positioning in oncology and autoimmune disease through biologics platforms.

Broad incumbents

• AstraZeneca: Global Big Pharma with deep oncology and innovative drug franchise, including ADC partnerships (Daiichi Sankyo). Overlaps with Fosun's oncology pipeline and serves as a benchmark for global pharma economics; potential partner/competitor for innovative oncology assets.
• Roche: Global oncology leader with PD-L1 franchise (Tecentriq) and biosimilar/innovative dual strategy. Direct overlap with Fosun's serplulimab in indications like SCLC, plus longstanding partnership reference noted in Fosun's GTM motion.

Emerging players

• Zai Lab: China-based global biopharma with licensing-driven model bringing innovative drugs to China. Similar strategic approach to Fosun's out-licensing model, focused on oncology and autoimmune disease with global development partnerships.

Others

• WuXi Biologics: Global biologics CDMO with significant biosimilar and biologics manufacturing capacity. Overlaps with Henlius (Fosun subsidiary) in biologics manufacturing capability and serves as infrastructure partner for the broader Chinese biologics ecosystem.
• Sinopharm Group: China's largest pharmaceutical distributor in which Fosun Pharma holds ~25% stake. Functions as channel partner (not competitor) for Fosun's domestic distribution, providing distribution moat and representing an alternative investment exposure to Chinese pharma sector.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments49 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fosun Pharma